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Aim: Metastatic melanoma patients were treated with patient-specific vaccines consisting of autologous
dendritic cells loaded with antigens from irradiated cells from short-term autologous tumor cell lines.
Patients & methods: A total of 72 patients were enrolled in a single-arm Phase I/II (NCT00948480) trial
or a randomized Phase II (NCT00436930). Results: Toxicity was minimal. Median overall survival (OS) was
49.4 months; 5-year OS 46%. A 5-year OS was 72% for 18 recurrent stage 3 without measurable disease
when treated and 53% for 30 stage 4 without measurable disease when treated. A total of 24 patients
with measurable stage 4 when treated (median of four prior therapies) had an 18.5 months median OS
and 46% 2-year OS. Conclusion: This dendritic cell vaccine was associated with encouraging survival in all
three clinical subsets. Clinicaltrial.gov NCT00436930 and NCT00948480.
First draft submitted: 3 December 2018; Accepted for publication: 25 February 2019; Published online:
31 May 2019
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Based on the responsiveness of metastatic melanoma to immunotherapies [1,2], immuno-oncology investigators
have been pursuing therapeutic vaccines to treat advanced melanoma for more than 25 years. Unfortunately,
various approaches have met with limited success [3]. Most notable disappointments were large-randomized trials
of an allogeneic cell line vaccine [4], a gp100 peptide antigen vaccine [5], and a combination of HLA-restricted
peptides injected with or without GM–CSF [6]. The first putative therapeutic vaccine to receive regulatory approval
for cancer treatment was sipuleucel-T, a mixture of dendritic cells (DC) and lymphocytes exposed to prostatic
acid phosphatase and GM–CSF and infused intravenously for castrate-resistant prostate cancer [7]. Approval was
based on a 4-month (18%) improvement in overall survival (OS). In 2015 intralesional injection of talimogene
laherparepvec, a cytolytic Herpes virus modified to secrete GM–CSF, was approved based on durable responses
in about 25% of patients with primarily regionally advanced or soft-tissue distant metastatic melanoma [8]. That
approach is based on autologous tumor antigens (ATA), but the systemic immune benefit may be limited by
injecting into the immunosuppressive tumor microenvironment. In fact, most responses were in the injected
lesions with limited responses in more distant lesions, suggesting that systemic immunization effects were limited.
In recent years, evidence has accumulated suggesting that the best source of antigens for vaccines is autologous
tumor because of unique neoantigens that result from nonsynonymous mutations [9,10]. Immunogenomics have
made it possible to identify nonsynonymous mutations, determine messenger sequences that can be transcribed
and translated, and predict the neoantigenicity and HLA-binding potential of specific molecules [11,12]. The best
way to present such ATA may be on autologous DC rather than directly injecting antigens [13–15]. Three different
preclinical animal models demonstrated that injections of DC loaded with specific neoantigens induced effective
CD4-mediated recognition of the same neoantigens and was associated with therapeutic benefit [16]. Similarly, in
melanoma patients, neoantigens derived from nonsynonymous mutations and loaded on DC were associated with
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new or increased immunoreactivity to the specific neoantigens [17]. A less complex approach is the use of autologous
tumor, especially short-term autologous cell lines as a source of ATA in as much as they include the entire repertoire
of neoantigens unique to that patient, including antigens that may be unique to the patient’s tumor initiating
cells [18–20].
The role of adjuvants in cancer vaccines is not clear, although historically adjuvants have been added to induce
inflammation at the site of cutaneous vaccine injections. There is a good rationale for using GM–CSF as an adjuvant
with vaccines [21,22], and it is a component of the two therapeutic cancer vaccines that have been approved for
marketing [7,8]. The GM–CSF has been used as a treatment in melanoma for many years [23], but never received
regulatory approval for that purpose. Repeated injections of subcutaneous GM–CSF monotherapy (daily for 2
weeks, off for 2 weeks) showed promise in single arm studies [24,25] but was no better than placebo in patients
with stage 3 or stage 4 metastatic melanoma that had been surgically resected [6], and was inferior to intralesional
cytolytic virus vaccine in patients with metastases that were accessible for injection [8].
For several years, we conducted clinical trials with autologous DC loaded with ATA (DC–ATA) derived from
short-term cell cultures and then admixed with GM–CSF at the time of injection [11,26–31]. The mechanism of action
for this DC vaccine (DCV) is believed to be the induction of new immune responses to ATA or enhancement of
weak existing immune responses. Two trials were conducted with DC–ATA in patients with metastatic melanoma.
A single-arm Phase I–II trial established safety and suggested an improvement in OS [26,27]. A randomized Phase
II trial confirmed safety and longer survival compared with an autologous tumor cell vaccine (TCV) consisting
of irradiated autologous tumor cells from short-term cell lines that were admixed with GM–CSF at the time of
subcutaneous injection [28,29]. In this report, we present 5-year survival data for all 72 metastatic melanoma patients
who were treated with patient-specific DCV. They were treated during 2001–2011 prior to adoption of antiBRAF/MEK treatment for patients whose tumors expressed BRAF mutations and prior to adoption of monoclonal
antibody checkpoint inhibitors including anti-CTLA-4 ipilimumab, and antiprogrammed death molecule-1 (PD1) products nivolumab and pembrolizumab. The purposes of this article are to: provide additional information
regarding manufacturing of the patient-specific DCV, present adverse-event data for all 72 patients, report survival
for specific cohorts of patients defined by stage and tumor burden at the time of treatment and compare survival
in those cohorts with published results for similar patients.
Patients & methods
Patients

All human subjects were treated in clinical trials that followed the principles outlined in the Declaration of Helsinki
and were approved by an appropriate institutional review board. Written informed consent was obtained from
all participants involved. Patients received their DC–ATA product in two sequential trials: an open-label Phase II
(clinicaltrials.gov NCT00436930, registered 15 February 2007) [26,27], and a randomized Phase II (NCT00948480,
registered 28 July 2009) [28,29]. Both trials were investigator-initiated and conducted under BB-IND 8554. The
single-arm trial enrolled 54 patients from 27 December 2000 to 17 April 2007. The 1:1 randomized Phase II trial
enrolled patients from 9 October 2007 to 13 December 2010. Eligibility criteria were identical in both protocols.
These included a diagnosis of either stage 4 distant metastatic or recurrent stage 3 melanoma, establishment of a
short-term autologous tumor cell line from a resected metastatic lesion, a Karnofsky Performance Status of 70–100,
typical Phase II criteria for organ function, and referral for enrollment by the patient’s managing physician. Patients
with treated brain metastases were eligible unless they had uncontrolled lesions. Patients with a diagnosis of an
active autoimmune disease, or an immunosuppressive disease, or receiving immunosuppressive medications were
ineligible as were patients with chronic infections including hepatitis B, hepatitis C and HIV. Concurrent anticancer
therapy was not permitted. All patients had undergone excision of a metastatic lesion (locoregional or distant) from
which a cell line had been established; thus, all had stage 4 or recurrent stage 3 melanoma at the time of tumor
harvest, but differed in terms of stage and measurability of disease at the time of treatment. Patients were referred
from all over the USA; however, per request of the US FDA, all injections were administered at one geographical
location.
Intermediate & final products

Short-term tumor cell lines
Typically patients underwent surgery as part of standard of care, usually to render them disease free, or as a palliative
or diagnostic procedure. However, in some instances patients with more widespread disease underwent resection
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of a lesion that was easily accessible to surgery, specifically for an effort to establish a tumor cell line that might be
used in making an investigational agent for a clinical trial. At the time of surgical resection, tumor samples were
collected locally in Newport Beach, California or at various geographic locations throughout the USA. Tumor was
transported in tissue culture media containing antibiotics provided in a transport kit for overnight delivery to a cell
biology laboratory located in Hoag Cancer Center in Newport, CA, USA.
The methods used to establish cell lines were the same in both eras in which these trials were conducted as
published previously [32–34]. Briefly, tissue was mechanically minced and/or enzymatically digested to create a single
cell suspension that was placed in tissue culture media and incubated. Alternatively, processed tumor samples were
cryopreserved and placed into cell culture at a later date. A successful cell culture was defined by morphology typical
of melanoma cells, continuous proliferation and initial growth to 50 million cells. Cultures were then expanded to
120 million cells in the single arm trial and to 220 million cells in the randomized trial. Immunophenotyping was
conducted with a panel of antibodies to various melanoma-associated antigens. For the single arm trial, tumor cell
cultures included coincubation with IFN-γ for 72 h just prior to irradiation, but IFN-γ was not added at the end
of manufacturing of melanoma cell lines in the randomized trial. For both trials, tumor cells were irradiated at a
dose of 100 Gy and cryopreserved before incubation with autologous DC. Irradiated tumor cells were confirmed to
be nonproliferative in a nonradioactive proliferation assay then stored in in AIM 5 serum-free and antibiotic-free
medium with 8% DMSO until they were thawed and washed prior to incubation with autologous DC.
Tumor cells for delayed type hypersensitivity skin testing
Individual aliquots containing 1 million irradiated tumor cells were stored in AIM 5 serum-free medium with
8% DMSO. At the time of intradermal injection, these were thawed, washed and resuspended in 1 ml normal
saline. Total 1 week before starting vaccine (week 0) patients were injected intradermally on the volar surface of
the forearm. Within 48–72 h, the test was interpreted by nursing staff as negative (no induration), weakly positive
(5–9 mm induration) or positive (≥1 cm induration). The test and interpretation was repeated 1 week after 3
weekly injections had been administered (week 4), and at weeks 12 and 24 in patients who remained on study.
Dendritic cells
The procedures for producing DC from peripheral blood monocytes were previously described [26–29,35]. Peripheral
blood mononuclear cells (PBMC) were obtained by leukapheresis procedures carried out in the Hoag Cancer Center.
For the single arm trial, PBMC were isolated by Ficoll–Paque™ (Amersham Biosciences, NJ, USA) density gradient
separation of the leukapheresis product and subsequent plastic adherence/wash steps. During the randomized trial,
R
Cell Separation System (Terumo BCT, CO, USA) closed cell selection system was used to enrich for
the Elutra
monocytes. After isolation of monocytes, immature DC was generated in a 6-day culture in AIM5 serum-free
media to which the cytokines IL-4 (250 IU/ml) and GM–CSF (1000 IU/ml) were added. During this time,
CD14-positive monocytes were converted into DC. For characterization purposes, monoclonal antibodies and
flow cytometry were used to determine the percentage of cells expressing CD80, CD86 and CD11c before and
after this culture process. Cell number and viability were recorded.
Autologous DC vaccines
All treatment doses for each patient were manufactured a single batch in which the DC and cryopreserved irradiated
tumor cells were coincubated for 12–18 h at a ratio of about 3:1 in T25 flasks. For each treatment dose, cells
were divided into ten fractions containing 1–33 million DC that had been coincubated with about 10 million
irradiated tumor cells. These were cryopreserved in individual vials containing AIM 5 serum-free medium and 8%
DMSO. One vial was used for safety testing including exclusion of bacterial or mycoplasma contamination and
confirmation of an endotoxin level <350 IU/ml.
Administration of DC vaccines

Preparation for injection
Just prior to administration, DCV was rapidly thawed in a 37◦ C water bath. The thawed cell suspension was then
rinsed in 10 ml of sterile AIM-V (antibiotic-free) medium in a 50 ml conical tube. A cell count was performed
prior to centrifugation and decantation of the wash phase. The cell pellet was then suspended in 1 ml saline and
500 μg of GM–CSF in a 1.5 ml vial, and finally drawn into a 3.0 ml syringe for injection with a 25-gauge needle
within 5 h of thawing.
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Treatment schedule
In both trials, each vaccine dose was injected subcutaneously in an extremity once a week for 3 weeks, and then
once a month for 5 months at weeks 8, 12, 16, 20 and 24. The same extremity was not used for consecutive
injections. Patients were monitored for toxicity, objective tumor response and progression free survival (PFS) and
OS. Concurrent anticancer therapy was not allowed, but patients could interrupt vaccine therapy for specific
interventions, then resume vaccine treatment.
Statistical analysis

Survival curves were generated using the method of Kaplan–Meier. Comparisons of proportions were made using
Pearson’s χ2 test or Fisher’s exact test. Averages were compared using the student’s t-test. Median survival was
estimated from the survival curve calculations.
Survival analyses were performed for the entire study population and for cohorts defined as: recurrent stage 3 with
no measurable disease following surgical resection, previously confirmed distant stage 4 disease but no measurable
disease at the time of treatment after surgical resection(s) and/or systemic therapy and measurable distant stage 4
disease. Survival was calculated from the date of enrollment for intent to treat; each patient was treated with his/her
vaccine product.
The OS was defined by the date of death regardless of cause. The PFS was defined by date of disease progression
or date of death, whichever came first. The PFS was estimated by the investigator based on medical and radiology
reports, and patient reporting. The protocol requested that scans can be performed at any time that there were
symptoms or signs of disease progression, and otherwise until disease progression at 3 months intervals in the first
year, every 6 months during the next 2 years, and then every 6 months out to 5 years.
Results
Cell products

Anatomic sites from which tumors were resected
Table 1 shows the anatomic origins of tumors from which the cell lines were derived that served as sources of
patient-specific ATA. Most tumors were obtained from readily accessible lymph nodes or cutaneous lesions, but
28% were obtained from viscera. At the time of tumor harvest, 29 patients had recurrent stage 3 disease, but only
18 were still stage 3 at the time of treatment.
Production of tumor cells
The overall success rate for tumor cell lines was 188/419 (44.9%) for all samples submitted, regardless of the quality
of the sample in terms of size, viability and contamination. Some patients had more than one sample submitted.
During the period in which the open-label trial was conducted cell lines were established for possible use for 110
patients from 227 metastatic melanoma samples (48.5%) [27]. During the period in which the randomized Phase II
trial was conducted, 78 cell lines were established from 192 metastatic melanoma samples (40.6%) [29]. As shown in
Table 2, it took an average of little over 3 months to establish tumor cell lines, and there were no differences in time
to successful establishment of a melanoma cell line by anatomic origin of the resected tumor specimen, geographic
location from which tumor was submitted, or whether patients had stage 4 or recurrent stage 3 melanoma at the
time of resection.
Production of dendritic cells
Table 3 summarizes data related to the generation of DC and the final DCV product. The DC production was
successful for all patients and an additional 13 patients during 2001–2006 for whom a DCV-treatment product was
manufactured, but never used because the patient was not referred for treatment (n = 12) or was ineligible (n = 1).
One patient underwent two leukapheresis procedures because of contamination of the first DC product; thus, DC
was successfully produced for clinical use for 85/86 leukapheresis products. From a DC production perspective,
the major difference between trials was the reliance on plastic adherence as opposed to the Elutra for monocyte
isolation for the randomized trial. Because of the increased efficiency for monocyte isolation by elutriation, fewer
total PBMC were obtained during the shorter leukapheresis procedure used during the randomized trial. However,
more monocytes were placed into culture in the randomized trial because of the improved efficiency of monocyte
collection.
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Table 1. Anatomic sources of tissue from which tumor cell lines were derived.
Tissue source

Patients (n)

Lymph nodes

(37)

Axilla and/or supraclavicular

15

Inguinal/femoral/iliac

10

Neck

5

Mediastinum

3

Retroperitoneal

2

Parotid

1

Popliteal

1

Viscera

(20)

Lung

7

Breast

3

Liver

2

Spleen

2

Small bowel

2

Adrenal

2

Bone

2

Soft tissue

(15)

Leg

6

Chest wall

4

Arm

2

Back

1

Orbit

1

Paraspinal

1

At time of tissue harvest, 29 were recurrent stage 3 and 43 were stage 4. At time of treatment, highest stage was 18 recurrent stage 3, 54 stage 4.

Table 2. Days to a successful culture and expansion of cancer cells.
Variable

Patients (n)

Mean number of days to successful
culture ± standard deviation

p-value

Tissue source:
– Lymph nodes

37

116.0 ± 69.2

– Viscera

20

88.6 ± 61.0

0.34

– Cutaneous

15

87.4 ± 68.0

0.20

– Recurrent stage 3

29

108.7 ± 69.1

– Stage 4

43

98.2 ± 66.8

0.50

– California

48

105.9 ± 75.5

0.56

– Non-California

24

95.4 ± 47.5

Stage at time of tumor collection:

Geographic source of tumor:

Specific trial and era:
– Single arm (2000–2007)

54

101.9 ± 66.1

– Randomized (2007–2010)

18

103.8 ± 72.7

0.92

Production of DC vaccine
In Table 3, the apparent differences in various phenotypic parameters on the final product likely reflect slight
differences in the way in which DC was manufactured for each trial, and the effect of exposure of TC to IFN-γ,
which was associated with a more rapid phagocytosis during incubation with DC. As a result, there were more
residual CD11c-negative cells in vaccine preparations for the randomized trial in which IFN-γ was not added at
the end of the cell culture, which reflects residual irradiated tumor cells that were not phagocytosed by DC. The
DCV products used in the randomized trial contained an average of 33% cells that were CD11c-negative, while
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Table 3. Summary data related to the generation of dendritic cells and the final dendritic cell vaccine products.
Cell characteristics

Single arm

Randomized

Combined

Mean number of cells obtained by apheresis (n)

10.0 × 109
(46)

6.7 × 109
(18)

9.1 × 109
(64)

Monocytes (CD14+ ), % (n)

17.3%
(54)

17.5%
(18)

17.4% (72)

Mean number of monocytes placed in culture to produce DC (n)

2.0 × 108
(44)

4.2 × 108
(18)

2.6 × 108
(62)

CD80 positive pre co-culture with irradiated tumor cells, % (n)

39.1%
(42)

15.3%
(17)

32.2%
(59)

CD86 positive pre co-culture with irradiated tumor cells, % (n)

75.5%
(42)

67.7%
(17)

73.3%
(59)

CD11c positive pre co-culture with irradiated tumor cells, % (n)

99.3%
(42)

86.4%
(17)

95.6%
(59)

Mean number irradiated tumor cells in co-culture (n)

80 × 106
(54)

115 × 106
(18)

88.8 × 106
(72)

Mean total number of cells in co-culture (n)

213 × 106
(54)

165 × 106
(18)

201 × 106
(72)

CD80 positive post co-culture with ITC, % (n)

37.5%
(52)

100%
(17)

52.9%
(69)

CD86 positive post co-culture with ITC, % (n)

71.9%
(52)

40.3%
(17)

64.1%
(69)

CD11c positive post co-culture with ITC, % (n)

87.7%
(52)

51.8%
(16)

79.2%
(68)

Number of DC (CD11c positive) per treatment dose (n)

17.7 × 106
(52)

8.7 × 106
(16)

15.6 × 106
(68)

Number of TC (CD11c negative) per treatment dose (n)

2.1 × 106
(52)

4.2 × 106
(16)

2.6 × 106
(68)

Total number of cells per treatment dose (n)

19.8 × 106
(52)

12.9 × 106
(16)

18.2 × 106
(68)

DC: Dendritic cell; ITC: Irradiated tumor cell; TC: Tumor cell.

in the open-label trial they represented only about 10%. Less than 2% of CD11c-negative cells in these samples
were lymphocytes; the majority of CD11c-negative cells were irradiated tumor cells that were not phagocytosed by
DC. This raised the issue of whether such a difference might have resulted in a different potency than could have
affected survival. However, as shown in Figure 1, OS curves for the two trials were quite similar. It is not clear what
the contribution of intact irradiated tumor cells was to the vaccine, but the DCV was associated with much longer
survival compared with TCV as a historical control [27], and as a contemporary control in the randomized trial of
DCV versus TCV [28,29].
Pooled clinical trial results

Patient characteristics
Median age was 52 years (range: 17–83 years), and was also 52 years in each of the Phase II trials. Table 4 shows the
proportions of different characteristics for all 72 patients and for the cohorts whose most advanced stage of disease
at the time of treatment were recurrent stage 3 (n = 18) without measurable disease, stage 4 without measurable
disease (n = 30) or stage 4 with measurable disease per response evaluation criteria in solid tumors (RECIST;
n = 24). A patient’s most advanced stage of disease was considered to be recurrent stage 3 (n = 18) even if they
had detectable or equivocal radiographic findings of distant metastatic disease if they had not been confirmed
histologically (n = 3). The median time from tumor collection to enrollment for treatment was 7.1 months, and
the median time from tumor collection to efforts to initiate a cell culture was 4.0 months. A total of 29 patients
had recurrent stage 3 at the time of tumor collection, but 11 (38%) had experienced distant progression by the
time of enrollment for treatment, and nine had measurable disease at that time. Of 33 patients with stage 4 disease
at the time of tumor collection, 15 (45%) had recurred and had measurable disease at the time of treatment, while
18 (55%) had no evidence of disease at that time, often because of additional treatment procedures – including
surgical resection of new metastases and stereotactic radiation for brain metastases. It is noteworthy that of the 54
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0
0

6

12

18

24

69
51
18

62
46
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55
41
14

52
40
12

Number at risk
All (n = 72)
Single arm (n = 54)
Randomized (n = 18)

72
54
18

30
Time (months)
48
37
11

36

42

46

54
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46
35
11

42
32
10

36
28
8

33
27
6

33
27
3

Figure 1. Overall survival for all 72 melanoma patients treated with autologous dendritic cell vaccines loaded with autologous tumor
antigens and survival in a single arm Phase II trial (n = 54) and in a randomized Phase II trial (n = 18).

patients, whose most advanced stage was stage 4, 14 (26%) had experienced brain metastases, and ten (19%) had
experienced hepatic metastases.
Staging and substaging for these patients was assigned per the seventh edition of AJCC staging [36]. Among the
patients with recurrent stage 3 melanoma, 14 had recurred one-, two-, three- and four-times. The highest substages
for these were N1b (n = 5), N2b (n = 1), N2c (n = 3) and N3 (n = 9). Among the 30 patients who had experienced
distant metastatic disease (stage 4) but did not have measurable disease per RECIST at the time of treatment, their
highest substages were M1a (n = 10), M1b (n = 4) and M1c (n = 16). Previous sites of metastases that were not
measurable at the time of treatment included liver (n = 6), brain (n = 5), bowel (n = 3) and bone (n = 2). Among
these 30 patients, the previous number of recurrences during the course of their disease were one (n = 5), two
(n = 16), three (n = 7), four (n = 1) and six (n = 1). Among the 24 patients with measurable disease at the time of
treatment, stages at that time were M1a (n = 5, 21%), M1b (n = 5, 21%) and M1c (n = 14, 58%). Among these
24 patients, the number of previous recurrences during the course of their disease were one (n = 1), two (n = 11),
three (n = 5), four (n = 3), five (n = 2) and six (n = 2).
As shown in Table 5, these patients were very heavily treated prior to receiving their patient-specific vaccines. As
shown in Table 4, the average number of prior therapies was 3.0 (range: 1–5) for the stage 3 cohort, 3.3 (range:
1–7) for the stage 4 nonmeasurable disease cohort and 3.9 (range: 1–7) for those with stage 4 measurable disease.
Table 5 also shows the categories of treatments received after initiating vaccine therapy. Among patients with stage
3 disease, there were six who received no additional therapy and remained disease free and alive at 5 years of
follow-up. Two other patients underwent resection of one regional thigh metastasis after completion of DCV and
then remained disease free and alive at 5 years of follow-up without other therapy. Another patient continued on
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Table 4. Baseline characteristics by stage and measurable disease at time of treatment.
Clinical feature

Recurrent stage 3
(n = 18)

Nonmeasurable
stage 4 (n = 30)

Measurable stage 4
(n = 24)

All (n = 72)

Age ⬎60 years (median 52 years)

4 (22%)

6 (20%)

9 (38%)

19 (26%)

Proportion male

9 (50%)

21 (70%)

15 (62%)

45 (62%)

Unknown primary

1 (6%)

7 (23%)

7 (29%)

15 (21%)

Acrolentiginous primary

1 (6%)

2 (7%)

1 (4%)

4 (6%)

Ocular primary

0

1 (3%)

1 (4%)

2 (3%)

Mucosal primary

0

0

0

0

Stage 3 at time of tumor collection

17 (100%)

2 (7%)

9 (42%)

29 (40%)

Stage 4 at time of tumor collection

0

28 (93%)

15 (62%)

43 (60%)

Lymph node source of tissue

14 (78%)

7 (23%)

11 (46%)

32 (44%)

Soft tissue source of tissue

4 (22%)

9 (30%)

8 (33%)

17 (24%)

Lung source of tissue

–

5 (17%)

2 (8%)

7 (10%)

Visceral met (not lung)

–

9 (30%)

3 (12%)

14 (19%)

Ave number prior therapies

3.0

3.3

3.9

3.4

Prior lymph node and/or soft tissue metastases

18 (100%)

16 (53%)

21 (88%)

55 (76%)

Prior lung metastases

–

8 (27%)

7 (29%)

20 (28%)

Prior breast metastases

–

2 (7%)

2 (8%)

4 (6%)

Prior bone metastases

–

2 (7%)

2 (7%)

4 (6%)

Prior gallbladder metastases

–

0

1 (4%)

1 (1%)

Prior adrenal metastases

–

1 (3%)

1 (4%)

2 (3%)

Prior bowel metastases

–

3 (10%)

4 (17%)

7 (10%)

Prior splenic metastases

–

4 (13%)

1 (4%)

5 (7%)

Prior liver metastases

–

7 (23%)

3 (12%)

10 (14%)

Prior brain metastases

–

6 (20%)

8 (33%)

14 (19%)

ECOG 0 or KPS 100

17 (94%)

23 (77%)

7 (29%)

47 (65%)

Elevated LDH at treatment

3 (17%)

7 (23%)

13 (54%)

23 (32%)

Anergic to common skin tests

3 (17%)

11 (37%)

3 (17%)

17 (24%)

Tumor DTH positive at baseline

0

2 (7%)

1 (4%)

3 (4%)

Tumor DTH positive after vaccine

3 (17%)

8 (27%)

2 (8%)

13 (18%)

DTH: Delayed type hypersensitivity test; ECOG: Eastern Cooperative Oncology Group; Mets: Metastasis; KPS: Karnofsky Performance Status; NED: No evidence of disease;
RT: Radiation therapy.

GM–CSF, then underwent resection and radiation to a distant bone metastasis, then remained disease free and
alive at 5 years of follow-up.
Among the 30 patients who had experienced distant metastases but did not have measurable disease at the time
of DCV treatment, 11 were alive and disease free after 5 years of follow-up. Of these 11, three received no additional
therapy, two were disease free but received some additional GM–CSF (both) and subcutaneous IL-2 (one), four
underwent resection of a single site of distant metastatic disease and then remained disease free (metastases to soft
tissue back, small bowel, celiac node and rectosigmoid), one underwent resection of a small bowel mass and received
whole brain irradiation followed by temozolomide and one underwent cyberknife treatment of a brain metastasis
followed by temozolomide. Among the 16 who survived 5 years, one subsequently received ipilimumab and later
IL-2 with tumor infiltrating lymphocytes, and one received nivolumab and later ipilimumab.
Among the 24 patients with measurable disease, three remained disease free and were alive 5 years after starting
DCV. One received no additional therapy, one received radiation therapy to a residual adrenal cell metastasis and one
had resection of a residual lymph node. Among the four patients who survived 5 years, none received nivolumab,
pembrolizumab or ipilimumab, but one did receive dabrafinib plus trametinib in addition to chemotherapy,
pazoponib, surgical resection and radiation for brain metastases, and resection of a small bowel metastasis.
Efficacy
Survival curves are shown in Figures 1 and 2. All survival curves are actual to 5 years rather than actuarial in as
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Table 5. Antimelanoma therapy pre- and post-dendritic cell vaccine.
Other therapies received

Stage 3 NMD (n = 18)

Stage 4 NMD (n = 30)

Stage 4 MD (n = 24)

Pre

Post

Pre

Post

Pre

Metastasectomy (ies) locoregional

18

3

2

1

9

Post
2

Metastasectomy (ies) distant

0

6

23

17

11

7

RT (not brain)

7

4

6

6

7

6

Brain RT

0

2

6

5

7

8

Chemotherapy

8

4

14

7

19

16

IL-2

6

2

15

7

13

2

IFN-␣

9

1

10

1

11

1

GM-CSF

5

3

11

4

8

1

Anti-VEGF

0

1

1

1

4

2

Anti-VEGF-TKI

0

0

0

0

1

4

Vaccine

2

2

7

3

0

1

Anti-BRAF

0

0

0

2

0

1

Anti-BRAF + Anti-MEK

0

0

0

0

0

1

Anti-CTLA4

0

0

0

4

1

5

Anti-PD1

0

0

0

1

0

0

None and no PD

0

6

0

3

0

2

CSF: Cerebrospinal fluid; LR: Locoregional; MD: Measurable disease; NMD: No measurable disease; PD: Progressive disease; PD1: Programmed death molecule 1; RT: Radiation
therapy; TKI: Tyrosine kinase inhibitor.

much as all patients were either deceased or followed to 5 years with none lost to follow-up. Two patients died of
unrelated cerebrovascular events, one stage 4 without measurable disease and one stage 4 with measurable disease.
OS for all & by trial

Figure 1 displays the OS for all 72 patients treated with DCV and for those treated in the single arm (n = 54) and
randomized trials (n = 18). All three curves were similar. The median survival for all 72 patients was 49.4 months
(95% CI: 38.6–60 months). The 3-year survival rate was around 60% overall and in each trial. In the single
arm open-label trial, median survival was greater than 60.0 months (95% CI lower limit 36.3 months) and the
5-year survival 50% [27], while the 18 patients treated with DCV in the randomized trial had a median survival of
43.4 months (95% CI: 18.6–60 months) and 5-year survival was 33% [29].
OS for all & by most advanced stage

The 5-year OS for the 18 patients whose most advanced stage was recurrent stage 3 was 72%. For the 54 patients
whose most advanced stage was stage 4, the median OS was 42.5 months with 1-, 2-, 3-, 4- and 5-year survival rates
of 83, 67, 57, 43 and 37%, respectively. However, this included patients who had measurable or nonmeasurable
disease at the time of treatment. Figure 2 shows OS curves for patients based on the extent of disease at the time
of treatment. Median OS was greater than 60 months for recurrent stage 3 (95% CI lower limit: 38.7 months;
n = 18) and for nonmeasurable stage 4 (n = 30), compared with 18.5 months (95% CI: 12.6–42.7 months) for
patients with measurable stage 4 disease (n = 24). The 3-year survival rates were 83, 73 and 38%, respectively.
Progression-free survival by most advanced stage

For all 72 patients, the median PFS was 5.4 months. Median PFS was 32 months for recurrent stage 3, 7.4 months
for nonmeasurable stage 4, and 3.4 months for measurable stage 4. The 3-year PFS rates were 44, 23 and 4%,
respectively.
Survival comparisons with published results

Because of the unique circumstances associated with harvesting tumor, establishing a cell line and creating a
patient-specific autologous TCV, there are no perfectly comparable patient populations for outcomes comparisons.
In terms of resected stage 3 disease, a large randomized trial was conducted in such patients, but most had N1a and
N2a disease [4]. In that trial, patients randomized to bacillus Calmette–Guérin (BCG) plus an allogeneic cell line
vaccine had a 5-year survival of 59%, and those randomized to BCG plus placebo had a 5-year survival of 68% [4].
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100

80

% surviving

60

40

20

Stage 3 (n = 18)

Stage 4 NM (n = 30)

Stage 4 M (n = 24)

0
6

0

12

18

24

30

36

42

48

54

60

15
22
9

14
20
8

13
18
5

13
16
4

13
14
4

Time (months)
Stage 3 (n = 18)
Stage 4 NM (n = 30)
Stage 4 M (n = 24)

Number at risk
18
30
24

18
29
22

17
27
18

16
26
13

16
25
11

15
23
10

Figure 2. Overall survival for melanoma patients treated with autologous dendritic cell vaccines loaded with autologous tumor
antigens whose stages of disease at the time of treatment were stage 3 (n = 18), stage 4 with nonmeasurable disease per RECIST
(n = 30), or measurable (M) disease per RECIST (n = 24).
M: Measurable; NM: Not measurable.

The 5-year survival in our trial for the 18 patients with recurrent stage 3 disease was 72% even though all had N1b,
N2b, N2c or N3 stage 3 disease, which are associated with a worse prognosis.
In a similar trial, patients with surgically resected stage 4 disease who were still free of disease were randomized
to BCG plus an allogeneic vaccine or BCG plus placebo [4]. Patients randomized to the placebo + BCG had a
median survival of 39 months and a 5-year OS of 45%, while those randomized to BCG + allogeneic vaccine had
a median survival of 32 months and 5-year OS of 40%. Another trial enrolled patients with resected stage 4 disease,
who had no disease at the time of treatment with an antimelanoma MART-1 peptide vaccine [37].
Their median survival was 46 months and 5-year OS 43%. In our DCV trial, patients surgically resected stage
4 disease who did not have measurable disease at the time of DCV therapy, the median survival was not reached at
5 years and the 5-year OS was 53%.
Another trial was limited to patients who were still free of disease after resection of either stage 3 or stage 4
melanoma, and were randomized to a multipeptide vaccine or placebo and GM–CSF or placebo if they had the
appropriate HLA type, or to GM–CSF or placebo if they did not have the appropriate HLA type [6]. The 5-year
OS rates were 54% for those who received the multipeptide vaccine, 51% for those who received placebo and 52%
for those who received GM–CSF. In our DCV trial, the 48 patients who had nonmeasurable stage 3 or stage 4
melanoma had a 5-year OS of 60%.
There are several reports of immunotherapy in patients with measurable metastatic melanoma. A compilation of
trials with the anti-CTLA4 antibody ipilimumab in patients with measurable metastatic disease revealed a median
survival of 11.4 months and 2-year OS of 22% [38]. A clinical trial of the anti-PD-1 monoclonal antibody nivolumab
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Table 6. Adverse events and laboratory abnormalities considered possibly attributable to autologous dendritic
cell vaccine (n = 72).
Event & grade (%)

0

1

2

3

4

5

Any

Injection site reaction

24

43

33

0

0

0

76

Anemia

58

35

7

0

0

0

42

WBC (high or low)

67

29

4

0

0

0

33

Bone/joint pain

72

28

0

0

0

0

28

Transaminasemia

76

22

1

0

0

0

24

Chills/rigors

78

22

0

0

0

0

22

Nausea/vomiting

83

12

7

0

0

0

19

Headache

82

12

3

4

0

0

18

Rash/itch

85

11

1

3

0

0

15

Fatigue/malaise

89

11

0

0

0

0

11

Fever

94

4

1

0

0

0

6

WBC: White blood count.

in previously treated melanoma patients was associated with a median OS of 16.8 months and a 5-year OS of
43% [39]. A randomized trial in patients healthy enough to receive high-dose IL-2 resulted in a median survival of
17.8 months and 5-year OS of 30% in those who received IL-2 + gp100 peptide vaccine, and 11.1 months and
18% OS in those who received IL-2 alone [40]. In our trial, the patients with measurable melanoma at the time
of DCV therapy had a median OS of 18.5 months and a 2-year OS of 46%. Thus, the survival for DCV-treated
patients compared favorably with other immunotherapies in all cohorts.
Toxicity
Treatment with these patient-specific vaccines was well tolerated and consistent with the adverse event profile for a
single injection of 500 μg of GM–CSF. Table 6 displays the adverse events reported for the 72 patients. There were
no grade 4 adverse events (AE), and only five patients experienced a grade 3 AE; three reported a grade 3 headache
and two reported a grade 3 skin rash. In contrast to what has been reported for monoclonal antibody checkpoint
inhibitors, there were no immune-related adverse events resulting from autoimmune organ inflammation [41–43].
Delayed type hypersensitivity skin test reactivity
All 72 patients had a baseline DTH test at week 0 and a repeat test at week 4. Only three had a positive tumor
DTH test at baseline; they survived 45, 53 and 60+ months. It is generally believed that patients who have a
positive DTH at baseline may already have an active immune response that could contribute to greater survival,
regardless of any biologic activity of a vaccine. Of the 69 with a negative DTH at baseline, eight (11.6%) converted
to positive at week 4, and five others had a positive tumor DTH at a later time point. One patient whose test
converted to positive died at 1.3 months of a cerebrovascular event that was not related to his melanoma or to
treatment. Median survival was >60 months for the ten who had a positive DTH at week 0 or 4 compared with
43.8 months for those who tested negative on both occasions. The proportions surviving more than 44 months
were 8/10 versus 30/62 (p = 0.090)
Discussion
This report summarizes manufacturing and clinical results for the 72 metastatic melanoma patients who were
treated with DCV between 2001 and 2011. It provides important information regarding the manufacturing and
reproducibility of comparable products in biologically heterogeneous patients. It also demonstrates the differing
benefits among patients stratified by stage and disease measurability suggesting survival benefit for all patient groups
in an era prior to general availability of BRAF/MEK and immune checkpoint inhibitors. All datasets on which the
conclusions of the report rely are available on request.
Feasibility

The ability to establish autologous tumor cell lines was similar regardless of the anatomic site of resection, regardless
of the stage of the patient at the time of resection and regardless of the geographic location where the tumor
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specimen was resected. The success rate for establishing tumors was similar in both trials as was the time it took to
establish a tumor cell line. From a clinical and commercial perspective, it would be highly desirable if the cancer
cell lines could be established more reliably and more rapidly.
The need to perform a surgical excision limits the pool of patients who could be treated with this approach.
While biopsies or needle aspirates are less invasive means of obtaining tumor tissue, the nonhomogeneous location
of cancer initiating cells within a tumor mass is likely to be associated with sampling error which would decrease
the rate of cell-line success. Our limited experience with needle biopsies of resected tumor lesions supports this
concern. It would also be highly desirable if such lines could be reliably established and expanded from blood
samples containing circulating tumor cells rather than having to rely on resected specimens.
The DC was reliably produced for all patients in both trials, but there were some differences between the trials
in terms of DC production and ATA loading. From a DC production perspective, the major difference was the
reliance on plastic adherence as opposed to the Elutra for monocyte isolation. The most striking difference in the
final product was the number of residual CD11c-negative cells in the treatment product in the randomized trial,
which reflects residual irradiated tumor cells that were not phagocytosed. For those 18 patients, on average 33%
of each dose were residual irradiated tumor cells, while in the open-label trial they represented only about 10%.
These differences did not translate into a difference in clinical outcome following vaccine therapy. The immune
response to DCV is quite different than that observed in patients treated with an irradiated tumor cell TCV [29].
Of particular interest was the change in IL-17 production, which is associated with a Th17 long-term memory
helper T cell response [44,45]. There was no evidence that differences in DC number, TC number or their relative
proportions in a given vaccine, was associated with any difference in outcome nor was OS dissimilar between the
two trials. Antigen loading might be better accomplished by lysing the tumor cells, which would also result in a
more consistent percentage of DC in the final product.
Toxicity

Repeated injections of these patient-specific vaccines were associated with minimal toxicity, and those adverse
events that were observed are typical of injections of GM–CSF. There were no severe or life-threatening immune
related adverse events. The only grade 3 toxicities were headaches that occurred in three patients, and grade 3 skin
rashes reported for two patients. This is in sharp contrast to the rates of grade 3–5 toxicities associated with IL-2
(near 100%), anti-CTLA-4 (30%), anti-PD-1 (15%), anti-CTLA4 plus anti-PD-1 (60%) and anti-BRAF/MEK
(60%) [41–43].
Clinical efficacy & comparison with other immunotherapies

These 72 patients were treated during 2001–2011. The major strength of the clinical data presented here is the
maturity of the follow-up data such that 5-year survival data was available for every patient with no patients lost
to follow-up, and the sample size of 72 patients which permitted some subset analyses based on stage and tumor
measurability. This is important because stage and presence of measurable disease were strongly associated with
both PFS and OS. The median survival of 49 months and the 5-year OS of 46% for all 72 patients is impressive
for this era, but there is no comparable historical control group for comparison because of the varying stages and
extent of disease at the time of treatment. However, as discussed in the results section, survival for DCV-treated
patients compared favorably with other treatments in every cohort including patients who had distant measurable
disease at the time of treatment. The DCV data becomes even more impressive when one considers the differences
in the patient populations in these trials. For instance, in the multipeptide trial 61% of the patients had resected
stage 3 disease including primary stage 3 [6], while in the DCV trials only 25% had stage 3 disease and all were
recurrent. The allogeneic vaccine trial included mostly primary stage 3 patients in one trial, and excluded patients
who had had brain metastases in the stage 4 trial [4]. The only data included for nivolumab was from the initial trial
that included heavily pretreated patients. No data for pembrolizumab was included because none of the published
studies provided survival data for patients with measurable disease who had received more than one systemic therapy
previously.
The PFS associated with DCV was much less impressive than the OS. Similarly, among the 24 patients who had
measurable disease per RECIST, no objective tumor remissions were reported during or immediately following the
period of treatment. We now know that absence of high objective response rates or prolonged PFS does not preclude
a survival benefit for some immunotherapies. Such discordance was anticipated based on experience in earlier trials
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with TCV [46]. Such discordance was also observed in trials of the anti-CTLA-4 antibody ipilimumab [5], and the
anti-prostate cancer cell immunotherapy sipuleucel-T [7].
The standard treatment of metastatic melanoma has changed since these vaccine trials were conducted and
response rates and long-term survival in advanced melanoma patients have steadily improved since 2010 as
newer agents have moved into first-line therapy. These include the anticytotoxic T lymphocyte antigen-4 (CTLA4) monoclonal antibody ipilimumab [5,37], targeted signal transduction inhibitors in patients with B600E/K
BRAF mutations [47–49] and monoclonal antibody inhibitors of the immune checkpoint PD-1 [40,50–54]. Treatment
continues to evolve as anti-BRAF/anti-MEK and anti-PD-1 therapies have become standard treatments in the
adjuvant setting for patients with regionally advanced melanoma or oligometastatic disease but are at high risk for
recurrence after surgical resection [55–58]. Initial treatment with combined anti-CTLA4 and anti-PD-1 has resulted
in higher response rates and long-term survival, but at the expense of grade 3–4 adverse events in more than 50%
of patients [59–61].
Anti-BRAF/MEK combinations are now approved for patients with BRAF mutations as first-line therapy for
unresectable and distant metastatic melanoma, and as adjuvant treatment for patients with high-risk stage 3
melanoma or resected stage 4 melanoma. The checkpoint inhibitors anti-CTLA-4 (ipilimumab) and anti-PD-1
antibodies nivolumab and pembrolizumab as well as the combination of nivolumab plus ipilimumab have also
been approved as first-line therapies for unresectable and distant metastatic melanoma, and as adjuvant therapies
for patients with high risk stage 3 melanoma or resected stage 4 melanoma. However, there appears to still be an
unmet need for vaccine strategies that can induce or enhance recognition of patient-specific ATA in addition to
using checkpoint inhibitors to block factors that are suppressing existing immune responses [19,20].
The vast majority of DCV-treated patients were injected before the wide-spread availability of anti-BRAF and
effective checkpoint inhibitors such as ipilimumab, nivolumab, or pembrolizumab, and few patients ever received
these other immune therapies; so their survival was not impacted by those agents. DCV should be additive or
synergistic with such therapies because of its mechanism of action to induce or enhance ATA recognition, rather
than blocking the suppression of existing anti-ATA immune responses. Treatment-related toxicity associated with
DCV was minimal; so it may easy to use in conjunction with other therapies. Because of its limited toxicity, and
unique mechanism of action resulting in targeting of patient-specific ATA including those on cancer initiating
cells, DCV may add additional benefit to these therapies, especially if ATA unique to cancer stem cells and early
progenitors are being targeted in this approach [14,18,62–64].
Conclusion
Patient-specific DCV therapeutic vaccines were well tolerated and associated with encouraging survival results in
patients with metastatic melanoma, including those with resected recurrent stage 3 disease, stage 4 patients both
with and without measurable disease at the time of treatment. For wider testing of this approach, the source of
autologous tumor antigen must be available more reliably and in a shorter period of time.
Future perspective
During the past 5 years, BRAF-MEK inhibitors and immune checkpoint inhibitors have displaced IL-2, IL-α and
cytotoxic chemotherapy as the treatments of choice for patients with advanced melanoma. During the next 5–
10 years, the benefits and limitations of BRAF-MEK inhibitors and immune checkpoint inhibitors will be further
clarified. It is already recognized that less than half of all metastatic melanoma patients derive long-term benefit
from these therapies; so, there is still an unmet need either for more effective and/or less toxic agents, or nontoxic
agents that are additive to or synergistic with, the anti-PD-1 checkpoint inhibitors. A high proportion of patients
with metastatic melanoma lacks a BRAF mutation and therefore do not benefit from anti-BRAF/MEK therapy. A
high proportion of patients also lack an underlying immune response, and therefore do not benefit from anti-PD-1
therapy. During the next 5–10 years, there were will be continued testing of vaccines in an effort to induce new
immune responses or enhance weak existing responses to patient-specific neoantigens. With further improvement
in manufacturing, DC vaccines loaded with autologous tumor cell antigens, including those expressed on tumor
initiating cells, will be poised to become an important adjunct to existing immunotherapies.
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Summary points
• A total of 45 men and 27 women with metastatic melanoma were treated with patient-specific therapeutic
vaccines during 2001–2011.
• The vaccines consisted of autologous dendritic cells loaded with antigens from irradiated autologous tumor cells
from a short-term cell culture derived from one or more surgically resected metastases.
• Tumor sources were lymph nodes (n = 37), viscera (n = 20) and soft tissue (n = 15).
• The antigen-loaded dendritic cells were admixed with GM–CSF (500 μg) and injected subcutaneously weekly for 3
weeks and monthly for 5 months at weeks 8, 12, 16, 20 and 24.
• The average number of doses injected was 7.3 of a possible 8.
• Treatment was well tolerated, highest grade adverse event was 3 in five of 72 patients.
• Median survival was 49.4 months and 5-year survival rate was 46%.
• A total of 5-year survival rates based on cohorts defined at the time of vaccine treatment were, 72% for 18
patients who were stage 3 without measurable disease and 53% for 30 patients who were stage 4 without
measurable disease.
• For the 24 patients who were stage 4 with measurable disease at the time of treatment, median survival was
18.5 months and 2-year survival rate was 46%.
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